Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Understanding the relationship between gut microbiome and CAR T-cell therapy response

Understanding the relationship between gut microbiome and CAR T-cell therapy response

Potential therapeutic can synergize with existing drugs to effectively destroy leukemia cells

Potential therapeutic can synergize with existing drugs to effectively destroy leukemia cells

Study pinpoints a splicing deregulation that causes therapeutic vulnerability in pediatric AML

Study pinpoints a splicing deregulation that causes therapeutic vulnerability in pediatric AML

Study pinpoints a key cause of metastasis from an aggressive form of pediatric brain cancer

Study pinpoints a key cause of metastasis from an aggressive form of pediatric brain cancer

Herpesvirus infection boosts host cellular immunity: Study

Herpesvirus infection boosts host cellular immunity: Study

Extended generation of blood cells in wild-type animals from pluripotent stem cells

Extended generation of blood cells in wild-type animals from pluripotent stem cells

Improved efficacy of advanced genome editing with machine learning

Improved efficacy of advanced genome editing with machine learning

Developing a potential drug molecule that targets STAT5

Developing a potential drug molecule that targets STAT5

Reversal of ADAR1 hyper-editing with small molecule inhibitor

Reversal of ADAR1 hyper-editing with small molecule inhibitor

MD Anderson and Replay launch new company pioneering T cell receptor NK cell therapies

MD Anderson and Replay launch new company pioneering T cell receptor NK cell therapies

Importance of epigenetic regulation in the recovery of T cells

Importance of epigenetic regulation in the recovery of T cells

Novel combination therapy shows promise in acute myeloid leukemia

Novel combination therapy shows promise in acute myeloid leukemia

Protein that facilitates cancer-causing viruses dodge the immune system

Protein that facilitates cancer-causing viruses dodge the immune system

Employing molecular anchor for more effective CAR immunotherapies

Employing molecular anchor for more effective CAR immunotherapies

Cedars-Sinai's Stem Cell and Bone Marrow Transplant Program recognized with two hallmarks of quality

Cedars-Sinai's Stem Cell and Bone Marrow Transplant Program recognized with two hallmarks of quality

Unboxing the mystery genome black box with the DNA sequencing method

Unboxing the mystery genome black box with the DNA sequencing method

Novel blood biomarker predicts a favorable response to CART cell therapy

Novel blood biomarker predicts a favorable response to CART cell therapy

Revealing the functional significance of DDX41 in great detail

Revealing the functional significance of DDX41 in great detail

DNA-based nanotransporters could improve treatment of cancers, other diseases

DNA-based nanotransporters could improve treatment of cancers, other diseases

Studies highlight bacteria accelerate the leukemia development in mice through specific viruses

Studies highlight bacteria accelerate the leukemia development in mice through specific viruses

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.